 Paula Araya
Concepts (115)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Down Syndrome | 6 | 2023 | 335 | 1.620 |
Why?
| | T-Lymphocyte Subsets | 1 | 2019 | 383 | 0.570 |
Why?
| | Autoimmunity | 2 | 2023 | 813 | 0.480 |
Why?
| | Interferon-alpha | 3 | 2020 | 186 | 0.350 |
Why?
| | Interferons | 4 | 2023 | 151 | 0.330 |
Why?
| | Melanoma, Experimental | 3 | 2019 | 89 | 0.330 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 111 | 0.330 |
Why?
| | CD8-Positive T-Lymphocytes | 4 | 2023 | 688 | 0.310 |
Why?
| | Proteome | 2 | 2022 | 340 | 0.300 |
Why?
| | Transcriptome | 2 | 2022 | 726 | 0.260 |
Why?
| | Dendritic Cells | 2 | 2019 | 435 | 0.260 |
Why?
| | Diabetic Neuropathies | 1 | 2023 | 79 | 0.200 |
Why?
| | Growth Disorders | 1 | 2022 | 77 | 0.200 |
Why?
| | Case-Control Studies | 4 | 2023 | 3004 | 0.190 |
Why?
| | Toll-Like Receptor 3 | 2 | 2019 | 26 | 0.190 |
Why?
| | Blood | 1 | 2022 | 96 | 0.190 |
Why?
| | Interferon Regulatory Factors | 1 | 2021 | 31 | 0.180 |
Why?
| | Janus Kinase 1 | 1 | 2020 | 23 | 0.180 |
Why?
| | Seroconversion | 1 | 2021 | 45 | 0.180 |
Why?
| | Janus Kinase 2 | 1 | 2020 | 31 | 0.180 |
Why?
| | Azetidines | 1 | 2020 | 31 | 0.180 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2022 | 286 | 0.180 |
Why?
| | Databases, Genetic | 1 | 2021 | 206 | 0.170 |
Why?
| | Poly A-U | 2 | 2019 | 3 | 0.170 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2019 | 339 | 0.170 |
Why?
| | Photochemotherapy | 1 | 2019 | 29 | 0.170 |
Why?
| | Integrin alpha Chains | 1 | 2019 | 22 | 0.160 |
Why?
| | Interferon Type I | 1 | 2019 | 128 | 0.160 |
Why?
| | Metabolome | 1 | 2021 | 282 | 0.150 |
Why?
| | Biomarkers | 3 | 2023 | 3408 | 0.150 |
Why?
| | Cellular Senescence | 1 | 2019 | 152 | 0.150 |
Why?
| | Receptors, Estrogen | 1 | 2021 | 372 | 0.150 |
Why?
| | Neoplasms, Experimental | 1 | 2019 | 151 | 0.150 |
Why?
| | Cell Lineage | 1 | 2019 | 309 | 0.150 |
Why?
| | Sulfonamides | 1 | 2020 | 445 | 0.140 |
Why?
| | Hypersensitivity | 1 | 2020 | 252 | 0.140 |
Why?
| | Gene Expression Profiling | 2 | 2021 | 1518 | 0.140 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2017 | 90 | 0.140 |
Why?
| | Heart Defects, Congenital | 1 | 2023 | 670 | 0.140 |
Why?
| | Antigens, CD | 1 | 2019 | 442 | 0.130 |
Why?
| | Interferon-gamma | 1 | 2019 | 719 | 0.130 |
Why?
| | Tumor Microenvironment | 1 | 2019 | 430 | 0.130 |
Why?
| | Lymphocyte Activation | 1 | 2019 | 1037 | 0.130 |
Why?
| | Interferon-beta | 1 | 2016 | 79 | 0.130 |
Why?
| | Neovascularization, Pathologic | 1 | 2017 | 281 | 0.120 |
Why?
| | Protein Kinase Inhibitors | 1 | 2020 | 785 | 0.120 |
Why?
| | Down-Regulation | 1 | 2017 | 594 | 0.120 |
Why?
| | Cell Differentiation | 1 | 2019 | 1701 | 0.100 |
Why?
| | Immunotherapy | 1 | 2016 | 474 | 0.100 |
Why?
| | Datasets as Topic | 2 | 2022 | 100 | 0.090 |
Why?
| | Humans | 11 | 2023 | 114709 | 0.090 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2093 | 0.090 |
Why?
| | Breast Neoplasms | 1 | 2021 | 1862 | 0.080 |
Why?
| | Young Adult | 2 | 2021 | 10471 | 0.070 |
Why?
| | Mice | 5 | 2023 | 14872 | 0.070 |
Why?
| | Proteomics | 2 | 2023 | 837 | 0.070 |
Why?
| | Mice, Inbred C57BL | 3 | 2020 | 4694 | 0.060 |
Why?
| | Adult | 3 | 2021 | 30561 | 0.060 |
Why?
| | Animals | 6 | 2023 | 31710 | 0.060 |
Why?
| | Female | 5 | 2021 | 59571 | 0.060 |
Why?
| | Cell Line, Tumor | 2 | 2021 | 2711 | 0.060 |
Why?
| | Intermediate Filaments | 1 | 2023 | 46 | 0.050 |
Why?
| | Signal Transduction | 3 | 2023 | 4517 | 0.050 |
Why?
| | Neurofilament Proteins | 1 | 2023 | 34 | 0.050 |
Why?
| | L-Selectin | 1 | 2023 | 25 | 0.050 |
Why?
| | Receptors, Interferon | 1 | 2023 | 47 | 0.050 |
Why?
| | Perforin | 1 | 2023 | 18 | 0.050 |
Why?
| | Patient Acuity | 1 | 2023 | 42 | 0.050 |
Why?
| | Male | 4 | 2021 | 55667 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2019 | 2570 | 0.050 |
Why?
| | Hypoalbuminemia | 1 | 2021 | 27 | 0.050 |
Why?
| | Access to Information | 1 | 2021 | 47 | 0.050 |
Why?
| | Seroepidemiologic Studies | 1 | 2021 | 138 | 0.040 |
Why?
| | Data Mining | 1 | 2021 | 100 | 0.040 |
Why?
| | Hematopoiesis | 1 | 2021 | 171 | 0.040 |
Why?
| | Protoporphyrins | 1 | 2019 | 17 | 0.040 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 167 | 0.040 |
Why?
| | Purines | 1 | 2020 | 159 | 0.040 |
Why?
| | Photosensitizing Agents | 1 | 2019 | 26 | 0.040 |
Why?
| | Inpatients | 1 | 2022 | 380 | 0.040 |
Why?
| | Complement Activation | 1 | 2021 | 340 | 0.040 |
Why?
| | Complement System Proteins | 1 | 2021 | 283 | 0.040 |
Why?
| | Pyrazoles | 1 | 2020 | 362 | 0.040 |
Why?
| | Homeostasis | 1 | 2021 | 573 | 0.040 |
Why?
| | Light | 1 | 2019 | 337 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2023 | 959 | 0.030 |
Why?
| | Metabolomics | 1 | 2021 | 521 | 0.030 |
Why?
| | Gene Silencing | 1 | 2017 | 171 | 0.030 |
Why?
| | Comorbidity | 1 | 2021 | 1448 | 0.030 |
Why?
| | Interferon Regulatory Factor-3 | 1 | 2016 | 17 | 0.030 |
Why?
| | Immunologic Surveillance | 1 | 2016 | 19 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2019 | 1083 | 0.030 |
Why?
| | CD11c Antigen | 1 | 2016 | 38 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2016 | 228 | 0.030 |
Why?
| | Phenotype | 1 | 2023 | 2797 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2020 | 720 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2021 | 1040 | 0.030 |
Why?
| | Membrane Transport Proteins | 1 | 2016 | 138 | 0.030 |
Why?
| | Carcinogenesis | 1 | 2016 | 177 | 0.030 |
Why?
| | Mice, Nude | 1 | 2016 | 630 | 0.030 |
Why?
| | Disease Progression | 1 | 2021 | 2381 | 0.030 |
Why?
| | Models, Animal | 1 | 2016 | 344 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2019 | 766 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2019 | 1950 | 0.030 |
Why?
| | Models, Biological | 1 | 2021 | 1621 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2023 | 3535 | 0.030 |
Why?
| | Prognosis | 1 | 2021 | 3330 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2016 | 1144 | 0.030 |
Why?
| | Liver | 1 | 2020 | 1637 | 0.030 |
Why?
| | Hospitalization | 1 | 2021 | 1752 | 0.020 |
Why?
| | Apoptosis | 1 | 2019 | 2363 | 0.020 |
Why?
| | Middle Aged | 2 | 2021 | 26740 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2187 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2021 | 9089 | 0.020 |
Why?
| | Adolescent | 1 | 2023 | 17854 | 0.020 |
Why?
|
|
Araya's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|